Alexion's Managed Access Agreement Only Partially Quashes Strensiq Cost Concerns
Executive Summary
Alexion has only managed to convince NICE to recommend Strensiq for treatment in a limited patient population with pediatric-onset hypophosphatasia. The news is a step forward after NICE initially declined the drug altogether, but the new recommendations highlight the difficulties companies face when trying to justify high orphan drug prices.
You may also be interested in...
Q1 Earnings In Brief: Celgene, Alkermes, Novo Nordisk, Acorda, Alexion
First quarter earnings are in full swing. Here is a look at what some companies are saying to analysts during their quarterly calls. Celgene talks up Revlimid; Alkermes bullish on Aristada launch; Victoza market share threatened by Trulicity; Acorda plans for Phase III in post-stroke; Soliris still backbone at Alexion.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.